UNSPSC 51341604: Rimantadine hydrochloride

This classification denotes a pegylated interferon alfa with the molecular formula C10H18N3O5(C2H4O)N(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q46947FE7K. European Medicines Agency schedules peginterferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16452MIG. The term peginterferon alfa-2a is a European Medicines Agency European Public Assessment Report System designation. Most nations schedule rimantadine hydrochloride under HS 29213099 and SITC 51453.

As of Q4 2014, RIMANTADINE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Rimantadine hydrochloride bears US NLM identifiers UMLS ID C0733408 and NCI Concept Code C61928. SMILES: NONE.

UNSPSC 51341604 Rimantadine hydrochloride is a Commodity code that in recent state and local procurement activity captures pharmaceutical supplies and related medical products far broader than the code's nominal antiviral-drug scope — state and local issuing bodies are soliciting naloxone, first-aid supplies, generic pharmaceuticals, and OTC products under this taxonomy. The code shows activity from state health and human services agencies, county health departments, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions. Work solicited includes annual supply of pharmaceutical products with quarterly or on-demand delivery, compliance with cGMP and DSCSA standards, maintenance of insurance coverages, E-Verify and drug-free workplace certification, and participation in authorized wholesaler networks. Issuing bodies typically require sealed or electronic bid submission, firm pricing for one-year minimum terms, and delivery within five to ten working days of purchase order. The mismatch between the code name and the actual goods being procured signals that state and local procurement offices tag pharmaceutical supplies with this commodity code regardless of active ingredient or therapeutic class.

Recent activity spans Florida, Texas, Minnesota, and Oregon through distinctly different procurement models. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response date and quarterly delivery to the county community health building. The City of Tampa posted IFB 26P00145 on March 25, 2026 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00, a March 13, 2026 bid deadline, and a Small Local Business Enterprise set-aside with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage market research before formal RFP issuance.